肿瘤微环境
癌症研究
TLR7型
免疫疗法
CD8型
巨噬细胞
癌症免疫疗法
化学
免疫学
医学
免疫系统
体外
Toll样受体
先天免疫系统
生物化学
作者
Yeon Jeong Yoo,Ryounho Eun,Hye-Min Park,Suhyeon Kim,Sei Hyun Park,Janghun Heo,Yong Taik Lim
出处
期刊:Small
[Wiley]
日期:2023-11-15
卷期号:20 (13)
被引量:2
标识
DOI:10.1002/smll.202307694
摘要
Abstract Although adoptive cell‐based therapy is illuminated as one of the promising approaches in cancer immunotherapy, it shows low antitumor efficacy because transferred cells adapt and alter toward a pro‐tumoral phenotype in response to the tumor's immunosuppressive milieu. Herein, nanoengineered macrophages anchored with functional liposome armed with cholesterol‐conjugated Toll‐like receptor 7/8 agonist (masked TLR7/8a, m7/8a) are generated to overcome the shortcomings of current macrophage‐based therapies and enhance the remodeling of the immunosuppressive tumor microenvironment (TME). The liposome‐anchored macrophages (LAMΦ‐m7/8a), are fabricated by anchoring dibenzocyclooctyne‐modified liposome(m7/8a) onto azido‐expressing macrophages via a bio‐orthogonal click reaction, are continuously invigorated due to the slow internalization of liposome(m7/8a) and sustained activation. LAMΦ‐m7/8a secreted ≈3 and 33‐fold more IL‐6 and TNF‐α than conventional M1–MΦ, maintained the M1 phenotype, and phagocytosed tumor cells for up to 48 h in vitro. Both intratumoral and intravenous injections of LAMΦ‐m7/8a induced effective antitumor efficacy when treated in combination with doxorubicin‐loaded liposomes in 4T1‐tumor bearing mice. It not only increases the infiltration of antigen‐specific CD8 + T cells secreting granzyme B, IFN‐γ, and TNF‐α within the TME, but also reduces myeloid‐derived suppressor cells. These results suggest that LAMΦ‐m7/8a may provide a suitable alternative to next‐generation cell‐based therapy platform.
科研通智能强力驱动
Strongly Powered by AbleSci AI